Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT03365791 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Start date: December 22, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.

NCT ID: NCT03335670 Recruiting - Clinical trials for Neuroendocrine Tumors

Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors

Start date: November 3, 2017
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the biodistribution of Gallium-68 Pentixafor in patients with Neuroendocrine tumors and to evaluate the repeatability of Gallium-68 Pentixafor uptake in normal organs and neuroendocrine tumors.

NCT ID: NCT03308682 Recruiting - Clinical trials for Neuroendocrine Tumors

177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Start date: April 30, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, non-controlled, non-randomized study to investigate the long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluation safety and dosimetry of 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors. A single dose of 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE will be injected intravenously. and monitored at 2, 24, 72,120 and 168 hours post-injection with semiquantitative method based on quantitative single-photon emission computed tomography/computed tomography (SPECT/CT) performance.

NCT ID: NCT03290079 Recruiting - Clinical trials for Neuroendocrine Tumors

Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas

Start date: November 17, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to: - Assess overall radiographic response rate (ORR) - Assess progression-free survival (PFS) - Test the safety and tolerability of Pembrolizumab

NCT ID: NCT03289741 Recruiting - Clinical trials for Neuroendocrine Tumors

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Start date: September 19, 2017
Phase: Phase 4
Study type: Interventional

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

NCT ID: NCT03288597 Recruiting - Clinical trials for Neuroendocrine Tumors

Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms

Start date: September 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological findings and prognosis. The study was designed to confirm thet clinical values of dual imagings for neuroendocrine tumors.

NCT ID: NCT03288402 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients

DIB-NET
Start date: January 2017
Phase: N/A
Study type: Interventional

Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite several limitations that include: lack of a reference CgA standard; wide variations depending on the used assay in different laboratories; and varying sensitivity ranges from 60 to 90% with low specificity <50%, depending on the population studied (Oberg et al. Endocrine Connections 2016). Surprisingly, and to the best of our knowledge, only three studies with small numbers of participants have been published that have investigated possible effects of food intake on the measurement of CgA. Most have been performed in healthy controls or patients on treatment with proton pump inhibitors for chronic gastritis (up to n = 11 per group) but only one study has investigated patients with GEP-NET, where n = 6 patients with gastric NET were included. In this study, the investigators aim to assess the time dependent effects of normally ingested diet (5-item English breakfast; or tea or coffee; or ongoing fasted state) on plasma chromogranin A measurements, using timed measurements over 180 min following an > 10 hours overnight fast, in a randomised double-crossover design. The investigators aimed to include 25 - 35 patients with a histologically confirmed diagnosis of a GEP-NET of varying primary tumour location, tumour stage, grade; and presence or absence of treatment with long acting somatostatin analogues; as well as 10 - 15 healthy controls. In an additional small subgroup of patients who are initiated on treatment with GLP-1 analogues i.e. for type 2 diabetes or obesity, the investigators aim to establish whether injection of GLP-1 analogues has any effects on plasma CgA measurements.

NCT ID: NCT03279601 Recruiting - Clinical trials for Neuroendocrine Tumors

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.In this prospective randomized phase II study, the investigators aim to compare the survival benefit as well as the safety forCapecitabine Combined With Dacarbazine(CAPDTIC) versus Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.

NCT ID: NCT03278379 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Avelumab in G2-3 NET

NET-002
Start date: September 20, 2017
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.

NCT ID: NCT03278275 Recruiting - Clinical trials for Neuroendocrine Tumors

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

Start date: November 20, 2017
Phase: Phase 2
Study type: Interventional

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).